Canlyniadau Chwilio - Shirish M. Gadgeel

Mireinio'r Canlyniadau
  1. 1
    Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer

    Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer gan Misako Nagasaka, Shirish M. Gadgeel

    Cyhoeddwyd 2017
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Racial differences in lung cancer.

    Racial differences in lung cancer. gan Shirish M. Gadgeel, Gregory P. Kalemkerian

    Cyhoeddwyd 2003
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Modern Staging of Small Cell Lung Cancer

    Modern Staging of Small Cell Lung Cancer gan Gregory P. Kalemkerian, Shirish M. Gadgeel

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    MET/HGF pathway activation as a paradigm of resistance to targeted therapies

    MET/HGF pathway activation as a paradigm of resistance to targeted therapies gan Brian Ko, Tianfang He, Shirish M. Gadgeel, Balázs Halmos

    Cyhoeddwyd 2017
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives

    Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives gan Joy Tang, R. Salama, Shirish M. Gadgeel, Fazlul H. Sarkar, Aamir Ahmad

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Up-Regulation of Sonic Hedgehog Contributes to TGF-β1-Induced Epithelial to Mesenchymal Transition in NSCLC Cells

    Up-Regulation of Sonic Hedgehog Contributes to TGF-β1-Induced Epithelial to Mesenchymal Transition in NSCLC Cells gan Ma'in Y. Maitah, Shadan Ali, Aamir Ahmad, Shirish M. Gadgeel, Fazlul H. Sarkar

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Retracted: Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines

    Retracted: Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines gan Shirish M. Gadgeel, Shadan Ali, Philip A. Philip, Antoinette J. Wozniak, Fazlul H. Sarkar

    Cyhoeddwyd 2009
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinum Refractory Non-small Cell Lung Cancer (NSCLC)

    Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinu... gan Shirish M. Gadgeel, John C. Ruckdeschel, Elisabeth I. Heath, Lance K. Heilbrun, Raghu Venkatramanamoorthy, Antoinette J. Wozniak

    Cyhoeddwyd 2007
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data

    Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data gan Manish Thakur, Julie J. Ruterbusch, Ann G. Schwartz, Shirish M. Gadgeel, Jennifer Beebe‐Dimmer, Antoinette J. Wozniak

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Racial Diversity of Actionable Mutations in Non–Small Cell Lung Cancer

    Racial Diversity of Actionable Mutations in Non–Small Cell Lung Cancer gan Aliccia Bollig‐Fischer, Wei Chen, Shirish M. Gadgeel, Angela S. Wenzlaff, Michele L. Coté, Ann G. Schwartz, Gerold Bepler

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs

    Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs gan Aamir Ahmad, Ma'in Y. Maitah, Kevin R. Ginnebaugh, Yiwei Li, Bin Bao, Shirish M. Gadgeel, Fazlul H. Sarkar

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling

    Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling gan Angel Qin, Adrienne Johnson, Jeffrey S. Ross, Vincent A. Miller, Siraj M. Ali, Alexa B. Schrock, Shirish M. Gadgeel

    Cyhoeddwyd 2018
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Comparison Between the 2021 USPSTF Lung Cancer Screening Criteria and Other Lung Cancer Screening Criteria for Racial Disparity in Eligibility

    Comparison Between the 2021 USPSTF Lung Cancer Screening Criteria and Other Lung Cancer Screening Criteria for Racial Disparity in Eligibility gan Chan Yeu Pu, Christine M. Lusk, Christine Neslund‐Dudas, Shirish M. Gadgeel, Ayman O. Soubani, Ann G. Schwartz

    Cyhoeddwyd 2022
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)–Medicare investigation of treatment patterns and overall survival

    Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)–Medicare investigation of treatment patterns and overall survival gan Jennifer Beebe‐Dimmer, Jon P. Fryzek, Cecilia Yee, Tapashi Dalvi, David H. Garabrant, Ann G. Schwartz, Shirish M. Gadgeel

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study

    Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study gan Patricia LoRusso, Anthony F. Shields, Shirish M. Gadgeel, Ulka N. Vaishampayan, Tina Guthrie, Thomas A. Puchalski, John Xu, Qi Liu

    Cyhoeddwyd 2010
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data

    Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data gan Priscila Gonçalves, Stephanie Peterson, Fawn D. Vigneau, Ronald Shore, William Quarshie, Khairul Islam, Ann G. Schwartz, Antoinette J. Wozniak, Shirish M. Gadgeel

    Cyhoeddwyd 2016
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Chronic Obstructive Lung Diseases and Risk of Non-small Cell Lung Cancer in Women

    Chronic Obstructive Lung Diseases and Risk of Non-small Cell Lung Cancer in Women gan Ann G. Schwartz, Michele L. Coté, Angela S. Wenzlaff, Alison L. Van Dyke, Wei Chen, John C. Ruckdeschel, Shirish M. Gadgeel, Ayman O. Soubani

    Cyhoeddwyd 2009
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials

    Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials gan Julien Mazières, Achim Rittmeyer, Shirish M. Gadgeel, Toyoaki Hida, David R. Gandara, Diego Cortinovis, Fabrice Barlési, Wei Yu, Christina Matheny, Marcus Ballinger, Keunchil Park

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up

    Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow... gan Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Balázs Halmos, Marina Chiara Garassino, Takayasu Kurata, Ying Cheng, Erin Jensen, Mark Shamoun, Kumar Rajagopalan, Luis Paz‐Ares

    Cyhoeddwyd 2024
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Soy Isoflavones Augment Radiation Effect by Inhibiting APE1/Ref-1 DNA Repair Activity in Non-small Cell Lung Cancer

    Soy Isoflavones Augment Radiation Effect by Inhibiting APE1/Ref-1 DNA Repair Activity in Non-small Cell Lung Cancer gan Vinita Singh‐Gupta, Michael C. Joiner, L. Runyan, Christopher K. Yunker, Fazlul H. Sarkar, Stephen R. Miller, Shirish M. Gadgeel, André Konski, Gilda G. Hillman

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: